Advertisement

Fostamatinib for the treatment of chronic immune thrombocytopenia

Nathan T. Connell and Nancy Berliner

Abstract

Fostamatinib is a spleen tyrosine kinase inhibitor recently approved for the treatment of chronic immune thrombocytopenia (ITP) in patients without adequate response to at least 1 prior line of therapy. This article reviews fostmatinib’s mechanism of action and its clinical safety and efficacy in 2 industry-sponsored multicenter phase 3 randomized controlled trials in North America, Australia, and Europe (FIT1 and FIT2). Cost comparisons are discussed as well as the role of fostamatinib in relation to other options for chronic ITP.

  • Submitted November 18, 2018.
  • Accepted February 20, 2019.
View Full Text